Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genmab A/S (GNMSF)

Genmab A/S (GNMSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genmab A/S CARL JACOBSENS VEJ VALBY G7 2500 DNK

www.genmab.com P: 45-7020-2728

Description:

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Key Statistics

Overview:

Market Capitalization, $K 18,813,486
Enterprise Value, $K 16,654,796
Shares Outstanding, K 65,370
Annual Sales, $ 2,392 M
Annual Net Income, $ 631,910 K
Last Quarter Sales, $ 603,220 K
Last Quarter Net Income, $ 192,920 K
EBIT, $ 826,260 K
EBITDA, $ 869,090 K
60-Month Beta 1.05
% of Insider Shareholders 1.54%
% of Institutional Shareholders 0.00%
Float, K 0
% Float 0.00%
Short Volume Ratio 0.17

Growth:

1-Year Return -31.26%
3-Year Return -28.04%
5-Year Return 57.43%
5-Year Revenue Growth 399.19%
5-Year Earnings Growth 213.83%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 2.94 on 05/02/24
Latest Earnings Date 05/08/24
Earnings Per Share ttm 14.30
EPS Growth vs. Prev Qtr -19.01%
EPS Growth vs. Prev Year 500.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GNMSF Ratios

Ratio
Price/Earnings ttm 19.66
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 20.80%
Return-on-Assets % 18.53%
Profit Margin % 26.42%
Debt/Equity 0.00
Price/Sales 7.28
Price/Cash Flow 22.79
Price/Book 4.52
Book Value/Share 0.00
Interest Coverage 6.98
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar